We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · July 30, 2020

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Patients With Advanced Melanoma

JAMA Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Oncology
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials
JAMA Oncol 2020 Jul 16;[EPub Ahead of Print], I Puzanov, A Ribas, C Robert, J Schachter, M Nyakas, A Daud, A Arance, MS Carlino, SJ O'Day, GV Long, KA Margolin, R Dummer, D Schadendorf, J Lutzky, PA Ascierto, A Tarhini, J Lin, R Mogg, B Homet Moreno, N Ibrahim, O Hamid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading